Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.

Thamer M, Zhang Y, Kaufman J, Cotter D, Dong F, Hernán MA.

JAMA. 2007 Apr 18;297(15):1667-74.

PMID:
17440144
2.

Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.

Thamer M, Zhang Y, Kaufman J, Kshirsagar O, Cotter D, Hernán MA.

Am J Nephrol. 2014;40(6):554-60. doi: 10.1159/000370334.

3.

Epoetin dosing and dialysis facility ownership.

Kliger AS, Nissenson AR.

JAMA. 2007 Aug 22;298(8):861-2; author reply 862-3. No abstract available.

PMID:
17712067
4.

Epoetin dosing and dialysis facility ownership.

Regidor DL, Kalantar-Zadeh K, Kovesdy CP.

JAMA. 2007 Aug 22;298(8):862; author reply 862-3. No abstract available.

PMID:
17712068
5.

Do resource utilization and clinical measures still vary across dialysis chains after controlling for the local practices of facilities and physicians?

Hirth RA, Turenne MN, Wheeler JR, Ma Y, Messana JM.

Med Care. 2010 Aug;48(8):726-32. doi: 10.1097/MLR.0b013e3181e3570a.

PMID:
20613666
6.

Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States.

Thamer M, Zhang Y, Kaufman J, Stefanik K, Cotter DJ.

Am J Kidney Dis. 2006 Jul;48(1):77-87.

PMID:
16797389
7.

Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.

Frankenfield D, Johnson CA, Wish JB, Rocco MV, Madore F, Owen WF.

Kidney Int. 2000 Feb;57(2):578-89.

8.

Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.

Winkelmayer WC, Chang TI, Mitani AA, Wilhelm-Leen ER, Ding V, Chertow GM, Brookhart MA, Goldstein BA.

Am J Kidney Dis. 2015 Jul;66(1):106-13. doi: 10.1053/j.ajkd.2015.02.339.

9.

An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.

Patel M, Thimons DG, Winston JL, Langholff W, McGowan T.

J Am Med Dir Assoc. 2012 Mar;13(3):244-8. doi: 10.1016/j.jamda.2010.09.009.

PMID:
21450214
10.

The production of dialysis by for-profit versus not-for-profit freestanding renal dialysis facilities.

Griffiths RI, Powe NR, Gaskin DJ, Anderson GF, de Lissovoy GV, Whelton PK.

Health Serv Res. 1994 Oct;29(4):473-87.

11.

Dialysis facility ownership and epoetin dosing in hemodialysis patients: a dialysis provider's perspective.

Lazarus JM, Hakim RM.

Am J Kidney Dis. 2007 Sep;50(3):366-70. No abstract available.

PMID:
17720515
12.

For-profit versus not-for-profit dialysis care for children with end stage renal disease.

Furth SL, Hwang W, Neu AM, Fivush BA, Powe NR.

Pediatrics. 1999 Sep;104(3 Pt 1):519-24.

PMID:
10469779
13.

Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.

McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF Jr; End-Stage Renal Disease Core Indicators Work Group..

Am J Kidney Dis. 2001 May;37(5):E36.

PMID:
11325701
14.

Use of epoetin in chronic renal failure.

Coyne DW.

JAMA. 2007 Apr 18;297(15):1713-6. No abstract available.

PMID:
17440149
15.

Dialysis facility ownership and epoetin dosing in hemodialysis patients: an overview.

Weiner DE, Levey AS.

Am J Kidney Dis. 2007 Sep;50(3):349-53. No abstract available.

PMID:
17720511
16.

Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.

Collins AJ, Monda KL, Molony JT, Li S, Gilbertson DT, Bradbury BD.

Am J Kidney Dis. 2014 Jun;63(6):997-1006. doi: 10.1053/j.ajkd.2013.10.052.

PMID:
24315770
17.

Dialysis facility ownership and epoetin dosing in hemodialysis patients: a view from Europe.

Macdougall IC.

Am J Kidney Dis. 2007 Sep;50(3):358-61. No abstract available.

PMID:
17720513
18.

Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients.

Powe NR, Griffiths RI, Anderson GF, de Lissovoy G, Watson AJ, Greer JW, Herbert RJ, Whelton PK.

Am J Kidney Dis. 1993 Oct;22(4):557-67.

PMID:
8213796
19.

Dialysis facility ownership and epoetin dosing in hemodialysis patients: a medical economic perspective.

Cohen JT, Neumann PJ.

Am J Kidney Dis. 2007 Sep;50(3):362-5. No abstract available.

PMID:
17720514
20.

Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.

Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R; Epoetin Zeta Study Group..

Curr Med Res Opin. 2008 Mar;24(3):625-37. doi: 10.1185/030079908X273264. Erratum in: Curr Med Res Opin. 2008 Oct;24(10):3007. Curr Med Res Opin. 2008 Apr;24(4):1155.

PMID:
18208642

Supplemental Content

Support Center